医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

QImaging Launches New Complete, Live Cell Imaging Solution

2014年08月20日 PM09:00
このエントリーをはてなブックマークに追加


 

SURREY, Canada

QImaging™ today launched a new, all-in-one camera package that supports demanding live cell fluorescence imaging requirements. The Live Cell Imaging Package provides researchers with the sensitivity of EMCCD and the versatility of sCMOS camera technologies by combining QImaging’s Rolera™ Thunder EMCCD and optiMOS™ sCMOS cameras. Now, researchers can address their unique imaging needs for a broader, more diverse set of scientific applications.

The Live Cell Imaging Package provides researchers with the sensitivity of EMCCD and the versatility ...

The Live Cell Imaging Package provides researchers with the sensitivity of EMCCD and the versatility of sCMOS camera technologies. (Photo: Business Wire)

Modern cell biology can require an array of optical imaging methods to answer each scientific question. Unfortunately, many digital imaging solutions force researchers to compromise on one or more imaging parameters such as having to trade sensitivity for frame rates or image resolution. Meeting these complex imaging parameters requires investment in varying technologies, and can be cost prohibitive.

The Live Cell Imaging Package addresses these physical constraints by combining two diverse technologies, enabling customers to seamlessly alternate between two cameras for optimized imaging support. The Package includes:

  • Rolera Thunder for low light capabilities with >90% quantum efficiency, large pixels and <1e- read noise using EMCCD technology
  • optiMOS for live cell imaging from 100 frames per second (fps) at full resolution to 1,630 fps in a sub-region
  • Easy, fast delivery and set up

The Rolera Thunder EMCCD camera is ideal for super resolution microscopy such as STORM and PALM as well as single molecule fluorescence, TIRF and FRAP applications.

More suited for routine fluorescence microscopy, the optiMOS sCMOS camera is ideal for cell biologists using live cell, multicolor fluorescence; biophysicists studying membrane dynamics and protein and lipid trafficking; as well as neuroscientists looking at ion transport such as electrophysiology, calcium imaging and ratiometric imaging.

Purchasing EMMCD and sCMOS products separately requires an investment of $50,000. QImaging is offering the Live Cell Imaging Package for $29,950 to increase the accessibility of these important research tools for every lab.

For more information about the Live Cell Imaging Package visit www.qimaging.com/LIVE-CELL.

About QImaging

QImaging designs and manufactures user-friendly CCD, EMCCD, CMOS and Scientific CMOS cameras for life science, machine vision and OEM applications. These affordable and diverse digital imaging solutions offer outstanding versatility, ease of use and reliability. Customers around the world use QImaging cameras to perform quantitative image analysis and acquire high-resolution images for publication. The company offers a comprehensive OEM Camera Program and maintains numerous third-party alliances with software companies and system integrators to consistently deliver imaging solutions and application-specific software that supports a broad range of bioscience and industrial applications. QImaging is headquartered in Surrey, Canada, and is a registered ISO 9001:2008 company.

© Copyright 2014, QImaging. All rights reserved. QImaging and the QImaging logo are registered trademarks, and optiMOS and Rolera are trademarks of QImaging. All other product and service names mentioned herein are the trademarks of their respective owners.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140820005092/en/

CONTACT

QImaging
Cyndy Nawrocki
Marketing Communications Director
+1-520-547-2745
office
+1-520-889-9933 main
cnawrocki@qimaging.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表